Time Frame |
Up to 64.7 Months
|
Adverse Event Reporting Description |
All randomized participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Arm/Group Title
|
Ramucirumab + Docetaxel
|
Placebo+Docetaxel
|
Arm/Group Description |
Ramucirumab (10 mg/kg) IV plus doce...
|
Placebo IV plus docetaxel (75 mg/m²...
|
Arm/Group Description |
Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
|
Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
|
|
|
Ramucirumab + Docetaxel
|
Placebo+Docetaxel
|
|
Affected / at Risk (%) |
|
Affected / at Risk (%) |
|
Total |
193/258 (74.81%)
|
|
209/265 (78.87%)
|
|
|
|
Ramucirumab + Docetaxel
|
Placebo+Docetaxel
|
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Total |
111/258 (43.02%)
|
|
107/265 (40.38%)
|
|
Blood and lymphatic system disorders |
|
|
Anaemia |
0/258 (0.00%)
|
0 |
4/265 (1.51%)
|
4 |
Blood loss anaemia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Febrile neutropenia |
17/258 (6.59%)
|
20 |
13/265 (4.91%)
|
14 |
Leukopenia |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
3 |
Neutropenia |
4/258 (1.55%)
|
5 |
2/265 (0.75%)
|
2 |
Pancytopenia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Cardiac disorders |
|
|
Arteriospasm coronary |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Cardiac arrest |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Cardiac failure |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Cardiac failure congestive |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Intracardiac thrombus |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Myocardial infarction |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Pericardial effusion |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Supraventricular tachycardia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Ear and labyrinth disorders |
|
|
Vertigo |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Endocrine disorders |
|
|
Adrenal insufficiency |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Gastrointestinal disorders |
|
|
Abdominal pain |
1/258 (0.39%)
|
2 |
1/265 (0.38%)
|
1 |
Anal fistula |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Ascites |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Colitis |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Constipation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Diarrhoea |
6/258 (2.33%)
|
6 |
4/265 (1.51%)
|
5 |
Enterocolitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Enterovesical fistula |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Fistula of small intestine |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gastric haemorrhage |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gastrointestinal haemorrhage |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Gastrointestinal ulcer |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Haemorrhoids |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Ileal perforation |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Intestinal ischaemia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Intestinal obstruction |
3/258 (1.16%)
|
3 |
2/265 (0.75%)
|
2 |
Intestinal perforation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Large intestine perforation |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Nausea |
2/258 (0.78%)
|
2 |
2/265 (0.75%)
|
2 |
Oesophagitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Rectal haemorrhage |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Small intestinal obstruction |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Small intestinal perforation |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Stomatitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Tooth disorder |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Upper gastrointestinal haemorrhage |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Vomiting |
3/258 (1.16%)
|
3 |
2/265 (0.75%)
|
2 |
General disorders |
|
|
Asthenia |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Chest pain |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Death |
2/258 (0.78%)
|
2 |
2/265 (0.75%)
|
2 |
Fatigue |
5/258 (1.94%)
|
5 |
2/265 (0.75%)
|
2 |
General physical health deterioration |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Generalised oedema |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Malaise |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Mucosal inflammation |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Non-cardiac chest pain |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Pain |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Pyrexia |
3/258 (1.16%)
|
3 |
9/265 (3.40%)
|
10 |
Sudden death |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Hepatobiliary disorders |
|
|
Cholelithiasis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Infections and infestations |
|
|
Abdominal abscess |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Appendicitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Bacteraemia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Bronchitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Cellulitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Clostridium difficile colitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Cystitis |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Device related infection |
3/258 (1.16%)
|
3 |
0/265 (0.00%)
|
0 |
Diverticulitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Gastroenteritis |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Gingivitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Infection |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Kidney infection |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Lower respiratory tract infection |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Neutropenic sepsis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pneumonia |
5/258 (1.94%)
|
5 |
8/265 (3.02%)
|
8 |
Pneumonia aspiration |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Pyelonephritis |
2/258 (0.78%)
|
2 |
2/265 (0.75%)
|
2 |
Respiratory tract infection |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Sepsis |
7/258 (2.71%)
|
7 |
5/265 (1.89%)
|
5 |
Stoma site abscess |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Toxic shock syndrome |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Urinary tract infection |
10/258 (3.88%)
|
11 |
11/265 (4.15%)
|
15 |
Urosepsis |
2/258 (0.78%)
|
2 |
5/265 (1.89%)
|
5 |
Injury, poisoning and procedural complications |
|
|
Fall |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Infusion related reaction |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Lower limb fracture |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Urostomy complication |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Investigations |
|
|
Blood creatinine increased |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Neutrophil count decreased |
2/258 (0.78%)
|
3 |
2/265 (0.75%)
|
3 |
Platelet count decreased |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Metabolism and nutrition disorders |
|
|
Decreased appetite |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Dehydration |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Diabetic metabolic decompensation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Hyperglycaemia |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Hyperkalaemia |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Hyponatraemia |
3/258 (1.16%)
|
3 |
0/265 (0.00%)
|
0 |
Musculoskeletal and connective tissue disorders |
|
|
Back pain |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Bone pain |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Fistula |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Muscular weakness |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Myalgia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
|
Tumour haemorrhage |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Nervous system disorders |
|
|
Basilar artery thrombosis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Cerebral ischaemia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Cerebrovascular accident |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Dizziness |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Headache |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Presyncope |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Subarachnoid haemorrhage |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Syncope |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Transient ischaemic attack |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Product Issues |
|
|
Device connection issue |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Psychiatric disorders |
|
|
Delirium |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Mental status changes |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Renal and urinary disorders |
|
|
Acute kidney injury |
3/258 (1.16%)
|
3 |
1/265 (0.38%)
|
1 |
Haematuria |
4/258 (1.55%)
|
4 |
6/265 (2.26%)
|
6 |
Hydronephrosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Renal failure |
3/258 (1.16%)
|
3 |
0/265 (0.00%)
|
0 |
Ureteric stenosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Urinary tract obstruction |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Reproductive system and breast disorders |
|
|
Female genital tract fistula |
1/49 (2.04%)
|
1 |
0/51 (0.00%)
|
0 |
Respiratory, thoracic and mediastinal disorders |
|
|
Chronic obstructive pulmonary disease |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Dyspnoea |
3/258 (1.16%)
|
4 |
3/265 (1.13%)
|
3 |
Epistaxis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Hiccups |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Laryngeal inflammation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Obstructive airways disorder |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Pleural effusion |
0/258 (0.00%)
|
0 |
7/265 (2.64%)
|
8 |
Pneumonitis |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Pneumothorax |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pulmonary embolism |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Pulmonary hypertension |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Skin and subcutaneous tissue disorders |
|
|
Dermatitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Rash |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Vascular disorders |
|
|
Aortic aneurysm |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Arterial haemorrhage |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Deep vein thrombosis |
2/258 (0.78%)
|
2 |
2/265 (0.75%)
|
2 |
Embolism |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Haematoma |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Hypertension |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Hypotension |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Venous occlusion |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Term from vocabulary, MedDRA 26.0
Indicates events were collected by systematic assessment
|
|
Frequency Threshold for Reporting Other Adverse Events
|
0%
|
|
Ramucirumab + Docetaxel
|
Placebo+Docetaxel
|
|
Affected / at Risk (%) |
# Events
|
Affected / at Risk (%) |
# Events
|
Total |
241/258 (93.41%)
|
|
251/265 (94.72%)
|
|
Blood and lymphatic system disorders |
|
|
Anaemia |
50/258 (19.38%)
|
87 |
76/265 (28.68%)
|
140 |
Blood loss anaemia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Febrile neutropenia |
9/258 (3.49%)
|
9 |
5/265 (1.89%)
|
5 |
Leukocytosis |
1/258 (0.39%)
|
1 |
3/265 (1.13%)
|
3 |
Leukopenia |
8/258 (3.10%)
|
25 |
5/265 (1.89%)
|
9 |
Lymph node pain |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Lymphopenia |
2/258 (0.78%)
|
7 |
2/265 (0.75%)
|
2 |
Neutropenia |
18/258 (6.98%)
|
36 |
14/265 (5.28%)
|
14 |
Thrombocytopenia |
6/258 (2.33%)
|
13 |
3/265 (1.13%)
|
3 |
Thrombocytosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Cardiac disorders |
|
|
Angina pectoris |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Arrhythmia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Atrial fibrillation |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Atrioventricular block first degree |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Bradycardia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Cardiac failure |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Cardiovascular disorder |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Left ventricular dysfunction |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Palpitations |
2/258 (0.78%)
|
3 |
2/265 (0.75%)
|
2 |
Pericardial effusion |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Right atrial enlargement |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Sinus bradycardia |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Sinus tachycardia |
0/258 (0.00%)
|
0 |
4/265 (1.51%)
|
4 |
Tachyarrhythmia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Tachycardia |
3/258 (1.16%)
|
3 |
2/265 (0.75%)
|
2 |
Congenital, familial and genetic disorders |
|
|
Haemophilia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Ear and labyrinth disorders |
|
|
Ear canal stenosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Ear discomfort |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Hypoacusis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Middle ear inflammation |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Otorrhoea |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Tinnitus |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Vertigo |
0/258 (0.00%)
|
0 |
3/265 (1.13%)
|
4 |
Vestibular disorder |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Endocrine disorders |
|
|
Adrenal insufficiency |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Hypothyroidism |
2/258 (0.78%)
|
3 |
1/265 (0.38%)
|
1 |
Eye disorders |
|
|
Dry eye |
3/258 (1.16%)
|
3 |
2/265 (0.75%)
|
2 |
Eczema eyelids |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Eye discharge |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Eye disorder |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Eye pain |
2/258 (0.78%)
|
4 |
0/265 (0.00%)
|
0 |
Eye pruritus |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Eyelid function disorder |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Eyelid oedema |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Eyelid ptosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Glaucoma |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Lacrimation increased |
24/258 (9.30%)
|
28 |
12/265 (4.53%)
|
12 |
Ocular discomfort |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Photopsia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Retinal vascular disorder |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Vision blurred |
3/258 (1.16%)
|
3 |
1/265 (0.38%)
|
1 |
Visual impairment |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Vitreous detachment |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Vitreous haemorrhage |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gastrointestinal disorders |
|
|
Abdominal discomfort |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Abdominal distension |
7/258 (2.71%)
|
7 |
5/265 (1.89%)
|
5 |
Abdominal pain |
20/258 (7.75%)
|
26 |
17/265 (6.42%)
|
22 |
Abdominal pain lower |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Abdominal pain upper |
12/258 (4.65%)
|
15 |
10/265 (3.77%)
|
10 |
Abdominal wall disorder |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Anal fistula |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Anal haemorrhage |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Anal incontinence |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Anal inflammation |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Angular cheilitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Ascites |
7/258 (2.71%)
|
8 |
1/265 (0.38%)
|
1 |
Cheilitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Colitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Constipation |
35/258 (13.57%)
|
46 |
45/265 (16.98%)
|
58 |
Diarrhoea |
81/258 (31.40%)
|
131 |
56/265 (21.13%)
|
81 |
Dry mouth |
11/258 (4.26%)
|
13 |
5/265 (1.89%)
|
5 |
Dyschezia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Dyspepsia |
9/258 (3.49%)
|
10 |
7/265 (2.64%)
|
7 |
Dysphagia |
6/258 (2.33%)
|
6 |
2/265 (0.75%)
|
2 |
Ectopic gastric mucosa |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Enterocolitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Epigastric discomfort |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Eructation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Faeces discoloured |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Flatulence |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Food poisoning |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gastric polyps |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Gastritis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gastrointestinal motility disorder |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gastrointestinal obstruction |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gastrooesophageal reflux disease |
3/258 (1.16%)
|
8 |
4/265 (1.51%)
|
4 |
Gingival atrophy |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gingival bleeding |
3/258 (1.16%)
|
3 |
0/265 (0.00%)
|
0 |
Gingival pain |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Glossitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Haematochezia |
3/258 (1.16%)
|
3 |
2/265 (0.75%)
|
2 |
Haemorrhoidal haemorrhage |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Haemorrhoids |
8/258 (3.10%)
|
9 |
2/265 (0.75%)
|
2 |
Hiatus hernia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Hyperchlorhydria |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Ileus |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Intestinal haemorrhage |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Intra-abdominal haematoma |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Large intestinal haemorrhage |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Lip blister |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Lip dry |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Melaena |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
2 |
Mouth ulceration |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Mucous stools |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Nausea |
71/258 (27.52%)
|
102 |
55/265 (20.75%)
|
82 |
Obstruction gastric |
1/258 (0.39%)
|
5 |
0/265 (0.00%)
|
0 |
Odynophagia |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Oral disorder |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Oral hyperaesthesia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Oral pain |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Periodontal disease |
1/258 (0.39%)
|
2 |
2/265 (0.75%)
|
2 |
Proctalgia |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Proctitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Rectal haemorrhage |
1/258 (0.39%)
|
1 |
3/265 (1.13%)
|
3 |
Rectal prolapse |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Rectal tenesmus |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Stomatitis |
66/258 (25.58%)
|
117 |
30/265 (11.32%)
|
36 |
Toothache |
1/258 (0.39%)
|
1 |
4/265 (1.51%)
|
4 |
Upper gastrointestinal haemorrhage |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Vomiting |
41/258 (15.89%)
|
62 |
40/265 (15.09%)
|
56 |
General disorders |
|
|
Administration site extravasation |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Administration site rash |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Asthenia |
29/258 (11.24%)
|
55 |
24/265 (9.06%)
|
38 |
Catheter site erythema |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Chest discomfort |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Chest pain |
1/258 (0.39%)
|
1 |
4/265 (1.51%)
|
4 |
Chills |
6/258 (2.33%)
|
7 |
9/265 (3.40%)
|
12 |
Extravasation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Face oedema |
3/258 (1.16%)
|
3 |
1/265 (0.38%)
|
1 |
Fatigue |
98/258 (37.98%)
|
186 |
106/265 (40.00%)
|
188 |
Gait disturbance |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
General physical health deterioration |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Generalised oedema |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Hypothermia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Influenza like illness |
14/258 (5.43%)
|
15 |
7/265 (2.64%)
|
7 |
Infusion site extravasation |
4/258 (1.55%)
|
4 |
0/265 (0.00%)
|
0 |
Infusion site reaction |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Injection site extravasation |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Injection site reaction |
5/258 (1.94%)
|
12 |
1/265 (0.38%)
|
1 |
Localised oedema |
1/258 (0.39%)
|
2 |
6/265 (2.26%)
|
6 |
Malaise |
18/258 (6.98%)
|
31 |
10/265 (3.77%)
|
16 |
Moaning |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Mucosal disorder |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Mucosal inflammation |
13/258 (5.04%)
|
26 |
4/265 (1.51%)
|
7 |
Nodule |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Non-cardiac chest pain |
4/258 (1.55%)
|
4 |
4/265 (1.51%)
|
6 |
Oedema |
3/258 (1.16%)
|
3 |
1/265 (0.38%)
|
1 |
Oedema peripheral |
38/258 (14.73%)
|
52 |
34/265 (12.83%)
|
44 |
Pain |
10/258 (3.88%)
|
14 |
8/265 (3.02%)
|
8 |
Peripheral swelling |
2/258 (0.78%)
|
3 |
0/265 (0.00%)
|
0 |
Pyrexia |
44/258 (17.05%)
|
66 |
42/265 (15.85%)
|
63 |
Swelling |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Swelling face |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Tenderness |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Thirst decreased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Hepatobiliary disorders |
|
|
Cholelithiasis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Hepatic failure |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Hepatic function abnormal |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Hepatic pain |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Jaundice |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Immune system disorders |
|
|
Allergy to arthropod sting |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Drug hypersensitivity |
1/258 (0.39%)
|
2 |
1/265 (0.38%)
|
1 |
Hypersensitivity |
2/258 (0.78%)
|
2 |
4/265 (1.51%)
|
5 |
Seasonal allergy |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Infections and infestations |
|
|
Abscess intestinal |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Anal abscess |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Bacteraemia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Bacteriuria |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Breast cellulitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Bronchitis |
4/258 (1.55%)
|
4 |
3/265 (1.13%)
|
3 |
Cellulitis |
2/258 (0.78%)
|
3 |
2/265 (0.75%)
|
2 |
Conjunctivitis |
5/258 (1.94%)
|
6 |
1/265 (0.38%)
|
1 |
Covid-19 |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Cystitis |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Dacryocystitis |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Device related infection |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Enterovirus infection |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Eye infection |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Fungal infection |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Furuncle |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Gastroenteritis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Gingivitis |
4/258 (1.55%)
|
4 |
2/265 (0.75%)
|
2 |
Helicobacter infection |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Herpes dermatitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Herpes virus infection |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Herpes zoster |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Infection |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Infective glossitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Influenza |
3/258 (1.16%)
|
3 |
1/265 (0.38%)
|
1 |
Kidney infection |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Lower respiratory tract infection |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Mucosal infection |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Nail bed infection |
1/258 (0.39%)
|
3 |
0/265 (0.00%)
|
0 |
Nail infection |
5/258 (1.94%)
|
7 |
1/265 (0.38%)
|
1 |
Nasopharyngitis |
5/258 (1.94%)
|
5 |
3/265 (1.13%)
|
3 |
Onychomycosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Oral candidiasis |
5/258 (1.94%)
|
5 |
3/265 (1.13%)
|
3 |
Oral fungal infection |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Oral herpes |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Paronychia |
2/258 (0.78%)
|
3 |
0/265 (0.00%)
|
0 |
Parotitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Perineal abscess |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Perineal infection |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Peritonitis bacterial |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pharyngitis |
1/258 (0.39%)
|
2 |
1/265 (0.38%)
|
1 |
Pneumonia |
1/258 (0.39%)
|
1 |
3/265 (1.13%)
|
5 |
Post procedural infection |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Postoperative wound infection |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pyelonephritis |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Pyelonephritis acute |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Respiratory tract infection |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Respiratory tract infection viral |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Rhinitis |
3/258 (1.16%)
|
5 |
1/265 (0.38%)
|
1 |
Sepsis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Sinusitis |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Skin infection |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Spinal cord infection |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Tinea pedis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Tonsillitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Tooth abscess |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Tooth infection |
3/258 (1.16%)
|
3 |
0/265 (0.00%)
|
0 |
Tracheitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Upper respiratory tract infection |
5/258 (1.94%)
|
5 |
9/265 (3.40%)
|
9 |
Urethritis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Urinary tract infection |
31/258 (12.02%)
|
38 |
34/265 (12.83%)
|
39 |
Viral infection |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Viral upper respiratory tract infection |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Injury, poisoning and procedural complications |
|
|
Contusion |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Eschar |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Fall |
3/258 (1.16%)
|
3 |
1/265 (0.38%)
|
1 |
Fracture |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Head injury |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Infusion related reaction |
7/258 (2.71%)
|
9 |
6/265 (2.26%)
|
6 |
Jaw fracture |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Joint injury |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Limb injury |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Nail injury |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pelvic fracture |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Penis injury |
0/209 (0.00%)
|
0 |
1/214 (0.47%)
|
1 |
Periorbital haematoma |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Post procedural haemorrhage |
3/258 (1.16%)
|
3 |
0/265 (0.00%)
|
0 |
Procedural nausea |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Procedural pain |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Rib fracture |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Skin abrasion |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Spinal fracture |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Stoma site pain |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Thermal burn |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Urinary tract stoma complication |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Vascular access complication |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Wound |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Wound complication |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Investigations |
|
|
Activated partial thromboplastin time prolonged |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Alanine aminotransferase increased |
9/258 (3.49%)
|
9 |
8/265 (3.02%)
|
8 |
Aspartate aminotransferase increased |
11/258 (4.26%)
|
12 |
9/265 (3.40%)
|
9 |
Blood alkaline phosphatase |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Blood alkaline phosphatase increased |
4/258 (1.55%)
|
4 |
11/265 (4.15%)
|
14 |
Blood bilirubin increased |
2/258 (0.78%)
|
6 |
1/265 (0.38%)
|
1 |
Blood calcium decreased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Blood creatine increased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Blood creatinine increased |
8/258 (3.10%)
|
8 |
21/265 (7.92%)
|
31 |
Blood lactate dehydrogenase increased |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Blood pressure decreased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Blood pressure increased |
3/258 (1.16%)
|
9 |
3/265 (1.13%)
|
7 |
Blood thyroid stimulating hormone increased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Blood urea increased |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Blood uric acid increased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Body temperature increased |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Carbon dioxide decreased |
2/258 (0.78%)
|
3 |
0/265 (0.00%)
|
0 |
Clostridium test positive |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Creatinine renal clearance decreased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Electrocardiogram st segment depression |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Gamma-glutamyltransferase increased |
1/258 (0.39%)
|
1 |
10/265 (3.77%)
|
13 |
Heart rate increased |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
International normalised ratio increased |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Lymphocyte count decreased |
5/258 (1.94%)
|
15 |
8/265 (3.02%)
|
26 |
Lymphocyte count increased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Neutrophil count decreased |
29/258 (11.24%)
|
93 |
29/265 (10.94%)
|
71 |
Neutrophil count increased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Platelet count decreased |
21/258 (8.14%)
|
56 |
6/265 (2.26%)
|
9 |
Platelet count increased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Protein total increased |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Protein urine |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Protein urine present |
1/258 (0.39%)
|
4 |
0/265 (0.00%)
|
0 |
Prothrombin time prolonged |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Total lung capacity decreased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Troponin t increased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Weight decreased |
23/258 (8.91%)
|
26 |
21/265 (7.92%)
|
28 |
Weight increased |
1/258 (0.39%)
|
1 |
3/265 (1.13%)
|
3 |
White blood cell count decreased |
19/258 (7.36%)
|
77 |
21/265 (7.92%)
|
54 |
White blood cell count increased |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
White blood cells urine |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
White blood cells urine positive |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Metabolism and nutrition disorders |
|
|
Acidosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Cachexia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Decreased appetite |
82/258 (31.78%)
|
128 |
64/265 (24.15%)
|
82 |
Dehydration |
8/258 (3.10%)
|
8 |
5/265 (1.89%)
|
5 |
Fluid retention |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gout |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Hypercalcaemia |
6/258 (2.33%)
|
11 |
12/265 (4.53%)
|
15 |
Hyperglycaemia |
8/258 (3.10%)
|
12 |
13/265 (4.91%)
|
15 |
Hyperkalaemia |
12/258 (4.65%)
|
26 |
7/265 (2.64%)
|
12 |
Hypermagnesaemia |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
2 |
Hypernatraemia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Hyperuricaemia |
10/258 (3.88%)
|
11 |
15/265 (5.66%)
|
17 |
Hypoalbuminaemia |
17/258 (6.59%)
|
25 |
26/265 (9.81%)
|
32 |
Hypocalcaemia |
2/258 (0.78%)
|
2 |
4/265 (1.51%)
|
6 |
Hypokalaemia |
3/258 (1.16%)
|
3 |
5/265 (1.89%)
|
7 |
Hypomagnesaemia |
4/258 (1.55%)
|
4 |
5/265 (1.89%)
|
7 |
Hyponatraemia |
7/258 (2.71%)
|
10 |
10/265 (3.77%)
|
11 |
Hypophagia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Hypophosphataemia |
6/258 (2.33%)
|
10 |
7/265 (2.64%)
|
8 |
Vitamin d deficiency |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Musculoskeletal and connective tissue disorders |
|
|
Arthralgia |
30/258 (11.63%)
|
39 |
26/265 (9.81%)
|
34 |
Arthritis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Back pain |
29/258 (11.24%)
|
36 |
21/265 (7.92%)
|
26 |
Bone pain |
15/258 (5.81%)
|
15 |
17/265 (6.42%)
|
19 |
Flank pain |
3/258 (1.16%)
|
3 |
5/265 (1.89%)
|
6 |
Groin pain |
4/258 (1.55%)
|
6 |
7/265 (2.64%)
|
7 |
Inguinal mass |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Intervertebral disc disorder |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Intervertebral disc protrusion |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Joint effusion |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Joint swelling |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Limb discomfort |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Muscle fatigue |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Muscle spasms |
2/258 (0.78%)
|
4 |
4/265 (1.51%)
|
4 |
Muscle twitching |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Muscular weakness |
5/258 (1.94%)
|
6 |
6/265 (2.26%)
|
7 |
Musculoskeletal chest pain |
4/258 (1.55%)
|
4 |
3/265 (1.13%)
|
3 |
Musculoskeletal pain |
1/258 (0.39%)
|
1 |
4/265 (1.51%)
|
4 |
Myalgia |
24/258 (9.30%)
|
39 |
23/265 (8.68%)
|
30 |
Myofascitis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Neck mass |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Neck pain |
3/258 (1.16%)
|
3 |
5/265 (1.89%)
|
7 |
Osteoarthritis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Osteonecrosis of jaw |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pain in extremity |
12/258 (4.65%)
|
15 |
16/265 (6.04%)
|
22 |
Pain in jaw |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Polymyalgia rheumatica |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pubic pain |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Sacral pain |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Spinal pain |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
|
Neuroma |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pyogenic granuloma |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Tumour necrosis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Tumour pain |
1/258 (0.39%)
|
1 |
9/265 (3.40%)
|
13 |
Nervous system disorders |
|
|
Ageusia |
0/258 (0.00%)
|
0 |
3/265 (1.13%)
|
3 |
Amnesia |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Ataxia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Clonus |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Depressed level of consciousness |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
3 |
Disturbance in attention |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Dizziness |
7/258 (2.71%)
|
8 |
9/265 (3.40%)
|
9 |
Dizziness postural |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Drooling |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Dysaesthesia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Dysarthria |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Dysgeusia |
28/258 (10.85%)
|
41 |
18/265 (6.79%)
|
19 |
Head titubation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Headache |
19/258 (7.36%)
|
27 |
14/265 (5.28%)
|
15 |
Hypoaesthesia |
2/258 (0.78%)
|
2 |
3/265 (1.13%)
|
3 |
Hypotonia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Lethargy |
3/258 (1.16%)
|
3 |
1/265 (0.38%)
|
1 |
Memory impairment |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Nervous system disorder |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Neuralgia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Neuropathy peripheral |
7/258 (2.71%)
|
9 |
13/265 (4.91%)
|
16 |
Neurotoxicity |
3/258 (1.16%)
|
3 |
2/265 (0.75%)
|
2 |
Paraesthesia |
5/258 (1.94%)
|
7 |
14/265 (5.28%)
|
15 |
Peripheral motor neuropathy |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Peripheral sensory neuropathy |
18/258 (6.98%)
|
23 |
22/265 (8.30%)
|
31 |
Peroneal nerve palsy |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Polyneuropathy |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Presyncope |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Radiculopathy |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Sciatica |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Somnolence |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Syncope |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Taste disorder |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Tremor |
2/258 (0.78%)
|
3 |
3/265 (1.13%)
|
4 |
Product Issues |
|
|
Device occlusion |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Psychiatric disorders |
|
|
Anxiety |
6/258 (2.33%)
|
6 |
8/265 (3.02%)
|
10 |
Confusional state |
1/258 (0.39%)
|
1 |
3/265 (1.13%)
|
4 |
Delirium |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Depression |
3/258 (1.16%)
|
3 |
4/265 (1.51%)
|
4 |
Depressive symptom |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Disorientation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Emotional distress |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Euphoric mood |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Insomnia |
23/258 (8.91%)
|
25 |
10/265 (3.77%)
|
11 |
Irritability |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Restlessness |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Sleep disorder |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Sleep talking |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Renal and urinary disorders |
|
|
Acute kidney injury |
5/258 (1.94%)
|
5 |
0/265 (0.00%)
|
0 |
Anuria |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Bladder pain |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Chromaturia |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Chronic kidney disease |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Cystitis interstitial |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Cystitis noninfective |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Dysuria |
3/258 (1.16%)
|
3 |
4/265 (1.51%)
|
4 |
Haematuria |
30/258 (11.63%)
|
48 |
19/265 (7.17%)
|
20 |
Hydronephrosis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Hydroureter |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Micturition urgency |
2/258 (0.78%)
|
2 |
0/265 (0.00%)
|
0 |
Nocturia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pollakiuria |
3/258 (1.16%)
|
3 |
4/265 (1.51%)
|
4 |
Polyuria |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Proteinuria |
33/258 (12.79%)
|
60 |
16/265 (6.04%)
|
28 |
Renal failure |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Renal impairment |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Renal pain |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Urethral haemorrhage |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Urinary fistula |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Urinary hesitation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Urinary incontinence |
1/258 (0.39%)
|
1 |
6/265 (2.26%)
|
6 |
Urinary retention |
1/258 (0.39%)
|
1 |
5/265 (1.89%)
|
6 |
Urinary tract obstruction |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Urinary tract pain |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Urine odour abnormal |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Reproductive system and breast disorders |
|
|
Breast pain |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Female genital tract fistula |
1/49 (2.04%)
|
1 |
0/51 (0.00%)
|
0 |
Genital haemorrhage |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
3 |
Genital ulceration |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Gynaecomastia |
1/209 (0.48%)
|
1 |
1/214 (0.47%)
|
1 |
Intermenstrual bleeding |
1/49 (2.04%)
|
2 |
0/51 (0.00%)
|
0 |
Oedema genital |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Pelvic discomfort |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Pelvic organ prolapse |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pelvic pain |
5/258 (1.94%)
|
5 |
4/265 (1.51%)
|
4 |
Penile pain |
0/209 (0.00%)
|
0 |
1/214 (0.47%)
|
1 |
Perineal pain |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Perineal ulceration |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Scrotal oedema |
3/209 (1.44%)
|
3 |
1/214 (0.47%)
|
1 |
Scrotal pain |
3/209 (1.44%)
|
3 |
0/214 (0.00%)
|
0 |
Scrotal swelling |
0/209 (0.00%)
|
0 |
1/214 (0.47%)
|
1 |
Testicular oedema |
0/209 (0.00%)
|
0 |
1/214 (0.47%)
|
1 |
Testicular pain |
1/209 (0.48%)
|
1 |
1/214 (0.47%)
|
1 |
Vaginal haemorrhage |
1/49 (2.04%)
|
1 |
1/51 (1.96%)
|
1 |
Vulval haemorrhage |
1/49 (2.04%)
|
1 |
0/51 (0.00%)
|
0 |
Vulvovaginal pruritus |
1/49 (2.04%)
|
1 |
0/51 (0.00%)
|
0 |
Respiratory, thoracic and mediastinal disorders |
|
|
Aphonia |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Bronchospasm |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Chronic obstructive pulmonary disease |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Chylothorax |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Cough |
21/258 (8.14%)
|
30 |
26/265 (9.81%)
|
29 |
Dry throat |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Dysphonia |
8/258 (3.10%)
|
10 |
3/265 (1.13%)
|
3 |
Dyspnoea |
32/258 (12.40%)
|
50 |
34/265 (12.83%)
|
40 |
Dyspnoea exertional |
1/258 (0.39%)
|
1 |
3/265 (1.13%)
|
3 |
Epistaxis |
39/258 (15.12%)
|
56 |
14/265 (5.28%)
|
16 |
Haemoptysis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Hiccups |
14/258 (5.43%)
|
21 |
8/265 (3.02%)
|
8 |
Hypoxia |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Laryngeal inflammation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Laryngeal pain |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Lung opacity |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Nasal dryness |
2/258 (0.78%)
|
2 |
1/265 (0.38%)
|
1 |
Oropharyngeal pain |
10/258 (3.88%)
|
11 |
5/265 (1.89%)
|
5 |
Pleural effusion |
4/258 (1.55%)
|
4 |
2/265 (0.75%)
|
2 |
Pneumonitis |
4/258 (1.55%)
|
4 |
2/265 (0.75%)
|
2 |
Productive cough |
4/258 (1.55%)
|
5 |
2/265 (0.75%)
|
2 |
Pulmonary embolism |
2/258 (0.78%)
|
2 |
2/265 (0.75%)
|
2 |
Pulmonary fibrosis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pulmonary haemorrhage |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Respiratory tract congestion |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Rhinitis allergic |
3/258 (1.16%)
|
3 |
3/265 (1.13%)
|
3 |
Rhinorrhoea |
7/258 (2.71%)
|
8 |
6/265 (2.26%)
|
6 |
Sinus congestion |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Tracheal inflammation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Upper respiratory tract congestion |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Upper respiratory tract inflammation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Upper-airway cough syndrome |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
3 |
Wheezing |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Skin and subcutaneous tissue disorders |
|
|
Acne |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Alopecia |
66/258 (25.58%)
|
79 |
94/265 (35.47%)
|
115 |
Decubitus ulcer |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Dermatitis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Dermatitis acneiform |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Drug eruption |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Dry skin |
11/258 (4.26%)
|
12 |
6/265 (2.26%)
|
6 |
Eczema |
2/258 (0.78%)
|
4 |
0/265 (0.00%)
|
0 |
Epidermolysis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Erythema |
6/258 (2.33%)
|
7 |
3/265 (1.13%)
|
3 |
Erythema multiforme |
0/258 (0.00%)
|
0 |
3/265 (1.13%)
|
3 |
Hyperhidrosis |
2/258 (0.78%)
|
2 |
2/265 (0.75%)
|
2 |
Nail bed disorder |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Nail bed inflammation |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Nail discolouration |
7/258 (2.71%)
|
7 |
15/265 (5.66%)
|
15 |
Nail disorder |
3/258 (1.16%)
|
3 |
3/265 (1.13%)
|
3 |
Nail dystrophy |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Nail ridging |
6/258 (2.33%)
|
7 |
3/265 (1.13%)
|
3 |
Nail toxicity |
2/258 (0.78%)
|
4 |
1/265 (0.38%)
|
1 |
Night sweats |
2/258 (0.78%)
|
2 |
2/265 (0.75%)
|
2 |
Onychalgia |
1/258 (0.39%)
|
5 |
0/265 (0.00%)
|
0 |
Onychoclasis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Onycholysis |
5/258 (1.94%)
|
7 |
2/265 (0.75%)
|
3 |
Onychomadesis |
8/258 (3.10%)
|
10 |
5/265 (1.89%)
|
5 |
Pain of skin |
3/258 (1.16%)
|
3 |
0/265 (0.00%)
|
0 |
Palmar-plantar erythrodysaesthesia syndrome |
19/258 (7.36%)
|
28 |
6/265 (2.26%)
|
15 |
Photosensitivity reaction |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Pruritus |
10/258 (3.88%)
|
11 |
12/265 (4.53%)
|
17 |
Rash |
11/258 (4.26%)
|
14 |
15/265 (5.66%)
|
18 |
Rash erythematous |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Rash maculo-papular |
0/258 (0.00%)
|
0 |
5/265 (1.89%)
|
5 |
Skin burning sensation |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Skin discolouration |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Skin disorder |
1/258 (0.39%)
|
2 |
0/265 (0.00%)
|
0 |
Skin exfoliation |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Skin fissures |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Skin hyperpigmentation |
2/258 (0.78%)
|
2 |
2/265 (0.75%)
|
2 |
Skin lesion |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Skin ulcer |
2/258 (0.78%)
|
3 |
0/265 (0.00%)
|
0 |
Urticaria |
5/258 (1.94%)
|
5 |
4/265 (1.51%)
|
4 |
Xeroderma |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Surgical and medical procedures |
|
|
Catheter placement |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Central venous catheterisation |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Endodontic procedure |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Nail operation |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Paracentesis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Skin lesion removal |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Tooth extraction |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Vascular disorders |
|
|
Cyanosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Deep vein thrombosis |
2/258 (0.78%)
|
2 |
4/265 (1.51%)
|
4 |
Embolism |
0/258 (0.00%)
|
0 |
2/265 (0.75%)
|
2 |
Flushing |
4/258 (1.55%)
|
5 |
2/265 (0.75%)
|
2 |
Haematoma |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Hot flush |
2/258 (0.78%)
|
2 |
2/265 (0.75%)
|
2 |
Hyperaemia |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Hypertension |
34/258 (13.18%)
|
66 |
15/265 (5.66%)
|
22 |
Hypotension |
7/258 (2.71%)
|
10 |
8/265 (3.02%)
|
8 |
Lymphocele |
1/258 (0.39%)
|
1 |
1/265 (0.38%)
|
1 |
Lymphoedema |
1/258 (0.39%)
|
1 |
2/265 (0.75%)
|
2 |
Pallor |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Pelvic venous thrombosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
2 |
Phlebitis |
2/258 (0.78%)
|
3 |
0/265 (0.00%)
|
0 |
Thrombosis |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Varicose vein |
1/258 (0.39%)
|
1 |
0/265 (0.00%)
|
0 |
Vasculitis |
1/258 (0.39%)
|
6 |
1/265 (0.38%)
|
1 |
Vena cava thrombosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Venous occlusion |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Venous thrombosis |
0/258 (0.00%)
|
0 |
1/265 (0.38%)
|
1 |
Term from vocabulary, MedDRA 26.0
Indicates events were collected by systematic assessment
|